LBI-HTA - Publications - Search - Subject: WF Respiratory system
Number of items at this level: 33.

Baumann, M. and Grössmann, N. (2016): Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 58.

Breuer, J. and Nachtnebel, A. (2014): Implantation of endobronchial valves in patients with emphysema. Update 2014. Decision Support Document 20/ Update 2014.

Breuer, J. and Nachtnebel, A. (2013): Afatinib (Giotrif®) for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s). DSD: Horizon Scanning in Oncology 41.

Dental and Pharmaceutical Benefits Agency (TLV), EUnetHTA and Main Association of Austrian Social Security Institutions (HVB), EUnetHTA and Agency for Quality and Accreditation in Health Care and Social Welfare (AAZ), EUnetHTA (2018): Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC). EUnetHTA report. DSD: Horizon Scanning in Oncology 77.

Falkner, E. and Wild, C. (2008): Clinical application of Tissue Engineering: An overview of International and Austrian Areas of Research with a critical analysis of selected applications . LBI-HTA Projektbericht 013.

Felder-Puig, R. and Wild, C. (2004): Current research and funding in the EU25 countries in the area of asthma in children. Fast-track study initiated by the Joint Research Centre of the European Commission. ITA-Projektbericht 27.

Gebetshuber, I. and Ratzer, B. and Wild, C. (1997): [Biomedical research projects and socio-scientific issues]. TA-Datenbank-Nachrichten 06 (02): 36-41.

Gebetshuber, I. and Ratzer, B. and Wild, C. (1997): [Biomedical research projects and socio-scientific issues] . Soziale Technik (1): 12-15.

Geiger-Gritsch, S. (2007): [Avastin® (Bevacizumab): Off-label use in cancer therapy]. HTA-Newsletter 58: 2.

Grössmann, N. (2016): Afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) who are refractory to erlotinib/gefitinib and afatinib monotherapy. DSD: Horizon Scanning in Oncology 59.

Hepperger, C. and Nachtnebel, A. (2011): S-1 (TeysunoTM) as first-line therapy for patients with advanced non-small cell lung cancer. DSD: Horizon Scanning in Oncology 19.

Hintringer, K. (2009): Cetuximab (Erbitux®) in EGFR-expressing Non-Small Cell Lung Cancer. DSD: Horizon Scanning in Oncology 02.

McGahan, L. (2018): Osimertinib (Tagrisso®) for the initial treatment of EGFR-mutated advanced non–small-cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 80.

McGahan, L. (2017): Durvalumab (Imfinzi™) for the treatment of patients with stage III non-small-cell lung cancer after prior chemoradiotherapy. DSD: Horizon Scanning in Oncology 76.

McGahan, L. (2017): Ceritinib (Zykadia®) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer. DSD: Horizon Scanning in Oncology 69.

McGahan, L. (2017): Atezolizumab (Tecentriq®) in previously treated non-small cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 68.

Nachtnebel, A. (2012): Erlotinib (Tarceva®) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations. DSD: Horizon Scanning in Oncology 22.

Nachtnebel, A. (2011): Gefitinib (Iressa®) for the 1st-line treatment of non-small cell lung cancer – 1st Update 2011. DSD: Horizon Scanning in Oncology 06 / Update 2011.

Nachtnebel, A. (2010): Endobronchial valve implantation for emphysema. Update 2010. Decision Support Document 20/ Update 2010.

Nachtnebel, A. (2010): Gefitinib (Iressa®) for the first-line treatment of non-small cell lung cancer . DSD: Horizon Scanning in Oncology 06.

Nachtnebel, A. and Ujeyl, M. (2015): Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer. DSD: Horizon Scanning in Oncology 53.

Patera, N. and Warmuth, M. (2011): Training therapy in physical medicine: Rapid systematic review. Decision Support Document 51.

Piso, B. and Mathis, S. and Geiger-Gritsch, S. and Mittermayr, T. (2009): Pumpless extracorporeal lung assist (PECLA). Systematic Review.. Decision Support Document 27.

Schiller-Frühwirth, I. and Kisser, A. (2016): Upper airway stimulation for moderate-to-severe sleep apnea. Decision Support Document 100.

Semlitsch , T. and Jeitler, K. (2013): Crizotinib (Xalkori®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) . DSD: Horizon Scanning in Oncology 35.

Warmuth, M. and Nachtnebel, A. (2012): Radiofrequency ablation of tumours of the lung and mediastinal lymph nodes. Decision Support Document 53.

Wild, C. (2018): Endobronchial valve implantation for emphysema. Update 2018. Decision Support Document 20/ Update 2018.

Wild, C. (2007): [FDA: Safety warning on erythropoietin]. ÖKZ: Österreichische Krankenhauszeitung 48 (07).

Wild, C. (2007): [FDA: Safety warning on erythropoietin]. HTA-Newsletter 58: 4.

Wild, C. (2003): [Computed tomography in screening for lung cancer]. HTA-Newsletter 21: 4.

Wild, C. (2002): [Laser-induced thermotherapy (LITT) in the treatment of malignant tumours]. HTA-Newsletter 06: 2.

Wild, C. (2001): [Hyperbaric oxygen]. HTA-Newsletter 03: 2.

Wild, C. and Jonas, S. and Frank, W. and Traunmüller, F. (2001): [Invasive aspergillosis: State of the art in diagnosis, treatment and conditions. An assessment]. ITA-Projektbericht 18.

This list was generated on Mon Jul 23 15:00:47 2018 CEST.